This is a working overview of circadian clock, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-01. Anything still debated is marked as such rather than presented as settled.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
QM (quantum-mechanical) methods are very powerful. However, they are computationally expensive, while the MM (classical or molecular mechanics) methods are fast but suffer from several limits (require extensive parameterization; energy estimates obtained are not very accurate; cannot be used to simulate reactions where covalent bonds are broken/formed; and are limited in their abilities for providing accurate details regarding the chemical environment). A new class of method has emerged that combines the good points of QM (accuracy) and MM (speed) calculations. These methods are termed mixed or hybrid quantum-mechanical and molecular mechanics methods (hybrid QM/MM). The most important advantage of hybrid QM/MM method is the speed. The cost of doing classical molecular dynamics (MM) in the most straightforward case scales O(n2), where n is the number of atoms in the system. This is mainly due to electrostatic interactions term (every particle interacts with every other particle). However, use of cutoff radius, periodic pair-list updates and more recently the variations of the particle-mesh Ewald's (PME) method has reduced this to between O(n) to O(n2). In other words, if a system with twice as many atoms is simulated then it would take between two and four times as much computing power. On the other hand, the simplest ab initio calculations typically scale O(n3) or worse (restricted Hartree–Fock calculations have been suggested to scale ~O(n2.7)).
It hosts public lectures and scholarly events, provides endowed Kluge fellowships, and awards the Kluge Prize for the Study of Humanity (now worth $1.5 million), the first Nobel-level international prize for lifetime achievement in the humanities and social sciences (subjects not included in the Nobel awards); Open World Leadership Center, established in 2000; by 2015 this program administered 23,000 professional exchanges for emerging post-Soviet leaders in Russia, Ukraine, and other successor states of the former USSR. Open World began as a Library of Congress project, and later was established as an independent agency in the legislative branch. Veterans History Project, congressionally mandated in 2000 to collect, preserve, and make accessible the personal accounts of American war veterans from World War I to the present day; National Audio-Visual Conservation Center opened in 2007 at a 45-acre site in Culpeper, Virginia, established with a gift of more than $150 million by the Packard Humanities Institute, and $82.1 million in additional support from Congress.
=== Classification criteria === In 2010, the 2010 ACR / EULAR Rheumatoid Arthritis Classification Criteria were introduced. The new criteria are not diagnostic criteria, but are classification criteria to identify disease with a high likelihood of developing a chronic form. However a score of 6 or greater unequivocally classifies a person with a diagnosis of rheumatoid arthritis. These new classification criteria overruled the "old" ACR criteria of 1987 and are adapted for early RA diagnosis. The "new" classification criteria, jointly published by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR), establish a point value between 0 and 10. Four areas are covered in the diagnosis:
Haycocknema perplexum: [Internet]. Wildlifehealthaustralia.com.au. 2018 [cited 26 March 2018]. Available from: https://www.wildlifehealthaustralia.com.au/Portals/0/Documents/FactSheets/Public%20health/Haycocknema%20perplexum%20Mar%202008%20(1.1).pdf Albendazole [Internet]. Pubchem.ncbi.nlm.nih.gov. 2018 [cited 26 March 2018]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/albendazole#section=Top
When Noriega created the PDF in 1983, he brought into its control Panama's customs and immigration apparatus, as well as the country's whole transportation network. This expansion of the military's role occurred simultaneously with a large growth in the cocaine trade, as well as in markets for weapons in various military conflicts in Central America. The profits the military reaped from these activities gave Noriega's military regime considerable financial clout. Noriega took control of most major newspapers by either buying a controlling stake in them or forcing them to shut down. The government also harassed, intimidated, or exiled individual journalists and editors. The newspaper La Prensa, which remained independent and was frequently critical of Noriega, had its staff intimidated and its offices damaged; eventually, it too was forced to close. In May 1984, Noriega allowed the first presidential elections in 16 years. Noriega and Díaz Herrera picked Nicolás Ardito Barletta Vallarino to be the PRD's candidate, with the intention of keeping him under close control. When the initial results showed Arias, who had the support of much of the opposition, on his way to a landslide victory, Noriega halted the count. After brazenly manipulating the results, the government announced that Barletta had won by a slim margin of 1,713 votes. Independent estimates suggested that Arias would have won by as many as 50,000 votes had the election been conducted fairly. More than 60,000 votes were not included in the final count.
Sources: en.wikipedia.org
=== Screenwriting === For her screenplay Look for Water, which she co-wrote with Dominic Mah, she was invited to the Sundance Screenwriters' Lab in June 2008. The screenplay has also received the Tribeca Film Festival L'Oreal Woman of Worth Vision Award, a Sundance CineReach grant, and a Sundance Institute Annenberg Feature Film Fellowship Grant.
This list of nuclides shows observed nuclides that either are stable or, if radioactive, have half-lives longer than one hour. This includes isotopes of the first 105 elements, except for 87 (francium), 102 (nobelium) and 104 (rutherfordium). More than 5,000 nuclides have been experimentally characterized, including isomers, of which this page presently includes 987.
=== Effects of early and late puberty onset === Several studies about puberty have examined the effects of an early or a late onset of puberty in males and females. In general, females who enter puberty late experience positive outcomes in adolescence and adulthood, while females who enter puberty early experience negative outcomes. Males who have earlier pubertal timing generally have more positive outcomes in adulthood but more negative outcomes in adolescence, while the reverse is true for later pubertal timing.
Fully automatic polarimeters are now widely used and simply require the user to press a button and wait for a digital readout. Fast automatic digital polarimeters yield an accurate result within a few seconds, regardless of the rotation angle of the sample. In addition, they provide continuous measurement, facilitating high-performance liquid chromatography and other kinetic investigations. Another feature of modern polarimeters is the Faraday modulator. The Faraday modulator creates an alternating current magnetic field. It oscillates the plane of polarization to enhance the detection accuracy by allowing the point of maximal darkness to be passed through again and again and thus be determined with even more accuracy. As the temperature of the sample has a significant influence on the optical rotation of the sample, modern polarimeters have already included Peltier elements to actively control the temperature. Special techniques as temperature controlled sample tubes reduce measuring errors and ease operation. Results can directly be transferred to computers or networks for automatic processing. Historically, accurate filling of the sample cell had to be checked outside the instrument, as an appropriate control from within the device was not possible. Nowadays a camera system can help to monitor the sample and accurate filling conditions in the sample cell. Furthermore, features for automatic filling introduced by few companies are available on the market. When working with caustic chemicals, acids, and bases it can be beneficial to not load the polarimeter cell by hand.
However, in a preprint study, Carnegie Mellon University researchers tested the behavior of agents in a simulated software company and found that none of the agents could complete a majority of the tasks assigned to them. Other researchers had similar findings with Devin AI and other agents in both formal business settings and freelance work. In June 2025, CNN argued that CEOs's statements on AI replacing their employees were a strategy to "[keep] workers working by making them afraid of losing their jobs." Tech companies have pressured employees to use generative AI models in their work, including AI coding agents. Brian Armstrong, the CEO of Coinbase, fired several employees who did not. Some business leaders have replaced some of their employees with agents, but have said that the agents would need more supervision than those employees. In October 2025, Futurism questioned whether Amazon's previously announced efforts to replace parts of its workforce with generative AI and AI agents could have led to the October 2025 outage of Amazon Web Services. Large technology companies such as Salesforce, Klarna and IBM announced layoffs in 2025, replacing hundreds of their employees in human resources or customer service with AI agents. However, Klarna later rehired several human employees. Yoshua Bengio warned at the 2025 World Economic Forum that "all of the catastrophic scenarios with AGI or superintelligence happen if we have agents". Financial authorities have warned that more complex and autonomous "agentic" AI could become a channel for systemic risk in finance.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.